Tokyo Tape
Sign in
← M3

Quarterly report · Q1

2413.TEDINET S100OUDD
Period2022-04-01 → 2022-06-30
Filed2022-08-05
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥57.0bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥208.2bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥46.4bn2021-04-01 → 2021-06-30Cons.Revenue IFRS
Operating income¥18.7bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income¥24.7bn2021-04-01 → 2021-06-30Cons.Operating profit loss IFRS
Profit before tax¥19.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax¥96.2bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥24.8bn2021-04-01 → 2021-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥12.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥63.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥15.8bn2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥13.5bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Net income¥16.9bn2021-04-01 → 2021-06-30Cons.Profit loss IFRS
Total assets¥357.5bnat 2022-06-30Cons.Assets IFRS
Total assets¥346.0bnat 2022-03-31Cons.Assets IFRS
Total assets¥272.0bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥82.4bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥82.0bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥275.1bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥264.0bnat 2022-03-31Cons.Equity IFRS
Net assets / equity¥211.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥207.3bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥268.8bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥257.8bnat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥206.2bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥88.8bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥104.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥79.9bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥89.1bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥9.4bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥52.1bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.1bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥14.7bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥23.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥6.1bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥12.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥16.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥11.3bn2021-04-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥17.862022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥94.062021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥23.232021-04-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥17.852022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥93.982021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.212021-04-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio75.2%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio74.5%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio75.8%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 53
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥1.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥471m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥5.5bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥5.2bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥267m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥7.2bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.0bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥162m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2022-04-01 → 2022-06-30¥20.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2022-04-01 → 2022-06-30¥19.3bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥951m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2022-04-01 → 2022-06-30¥14.9bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥2m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2022-04-01 → 2022-06-30¥4.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2022-04-01 → 2022-06-30¥10.2bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2022-04-01 → 2022-06-30¥9.9bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥304m
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2022-04-01 → 2022-06-30¥1.4bn
—segment totalrevenue2022-04-01 → 2022-06-30¥58.0bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥56.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥1.7bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥19.3bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥947m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥947m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥144m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue2021-04-01 → 2021-06-30¥4.9bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.9bn
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥26m
jpcrp040300-q1r_E05425-000Career Solutionreportable segmentsegment profit2021-04-01 → 2021-06-30¥2.5bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue2021-04-01 → 2021-06-30¥4.8bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue external2021-04-01 → 2021-06-30¥4.6bn
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥195m
jpcrp040300-q1r_E05425-000Evidence Solutionreportable segmentsegment profit2021-04-01 → 2021-06-30¥858m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue2021-04-01 → 2021-06-30¥18.9bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue external2021-04-01 → 2021-06-30¥18.2bn
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥690m
jpcrp040300-q1r_E05425-000Medical Platformreportable segmentsegment profit2021-04-01 → 2021-06-30¥8.2bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue2021-04-01 → 2021-06-30¥12.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue external2021-04-01 → 2021-06-30¥12.7bn
jpcrp040300-q1r_E05425-000Overseasreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥12m
jpcrp040300-q1r_E05425-000Overseasreportable segmentsegment profit2021-04-01 → 2021-06-30¥13.0bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentrevenue external2021-04-01 → 2021-06-30¥5.3bn
jpcrp040300-q1r_E05425-000Site Solutionreportable segmentsegment profit2021-04-01 → 2021-06-30¥520m
—segment totalrevenue2021-04-01 → 2021-06-30¥46.6bn
—segment totalrevenue external2021-04-01 → 2021-06-30¥45.7bn
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥923m
—segment totalsegment profit2021-04-01 → 2021-06-30¥25.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 594
ItemContextValueUnit
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration52000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration2341000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-9249000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration-15503000000JPY
Cash and cash equivalents IFRSPrior2YearInstant89144000000JPY
Cash and cash equivalents IFRSPrior1YearInstant104253000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant79894000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant88751000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember18242000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember4638000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember4858000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember5329000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember12650000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember45716000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember687000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSPrior1YTDDuration46403000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember690000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember195000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember26000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember－JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember12000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember923000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember24000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-947000000JPY
Intersegment revenue IFRSPrior1YTDDuration－JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember18932000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember4833000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember4883000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember5329000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember12662000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember46639000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember711000000JPY
Revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-947000000JPY
Revenue IFRSPrior1YTDDuration46403000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember8179000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember858000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember2466000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember520000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OverseasReportableSegmentMember12952000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReportableSegmentsMember24975000000JPY
Operating profit loss IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000OtherEmergingBusinessMember-180000000JPY
Operating profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-144000000JPY
Operating profit loss IFRSPrior1YTDDuration24651000000JPY
Finance income and expenses net IFRSPrior1YTDDuration112000000JPY
Profit loss before tax IFRSPrior1YTDDuration24763000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000MedicalPlatformReportableSegmentMember656000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000EvidenceSolutionReportableSegmentMember40000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000CareerSolutionReportableSegmentMember22000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration_jpcrp040300-q1r_E05425-000SiteSolutionReportableSegmentMember264000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass